Lumos Pharma Gets $14M

Austin-based biopharmaceuticals developer Lumos Pharma said yesterday afternoon that it has raised $14M in a Series A funding, to go towards its development of treatments for Creatine Transporter Deficiency. The company said the funding was co-led by Sante Ventures and New Enterprise Associates. Lumos said the funding goes towards preclinical and clinical development of its lead compound. The company said Creatine Transporter Definiciency shows up as symptoms of mental retardation and global developmental delay, severe expressive speech and language delay, autistic behavior, and epilepsy. The company is led by Rick Hawkins and Jon Szxe. Kevin Lalande of Sante Ventures and Ed Mathers of NEA will join the company's board with the funding.